The University of Pennsylvania and Avid Radiopharmaceuticals, which had each been accused of infringing on patents related to Alzheimer's disease research, were awarded attorney fees in the case after they were victorious in a federal jury trial three years ago.

Following the jury decision were posttrial motions and a fruitless appeal to the U.S. Court of Appeals for the Federal Circuit filed by the plaintiff in the case, the Alzheimer's Institute of America.

One of the U.S. Supreme Court's decisions from last year that recalibrated the fee-shifting model in patent cases formed the basis of the decision to award attorney fees here.